12
Oct
2015
Who Deserves To Be Called a Founder, and Who Doesn’t?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2015
Vertex Takes Heat, Valeant Takes Even More, and Express Scripts Cuts a Deal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2015
GlaxoSmithKline: A Bunch of Bozos, Or Crazy Like a Fox?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2015
The Immune System as a Metaphor for the Turing Pharma Mess
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2015
Fallout from the Drug Pricing Fiasco, the New Thing in Genome Editing & More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Oct
2015
The Next Macro (Phage) Thing in Immuno-Oncology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Sep
2015
What Happens After The Gouging? Lock Pharma & The Payers in a Swiss Hotel
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Sep
2015
The Mother of All Drug Pricing Controversies, Slingshots at FDA Nominee, and Nobel Handicapping
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Sep
2015
A Timeline of the Turing Pharma Controversy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Sep
2015
Seattle Subscribers: Come Talk Biotech Today at the TR Meetup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Sep
2015
The McKinsey Alumni: Where Are They Wielding Influence?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Sep
2015
Just Snags $15M From Merck, Lilly, ARCH for Low-Cost Biotech Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Sep
2015
New FDA Commish, Lilly’s Diabetes Stunner, and a Dust-Up Over Immortality
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Sep
2015
Interlocking Relationships Make VC and Pharma Go Round, Not Just Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Sep
2015
Post-Labor Day Hangovers, Ipi-Nivo Combo Data & the PCSK9 Pricing Debate
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2015
Medical Device Innovation Is on Life Support. What Will Revive It?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Sep
2015
Insider Selling at Biotech’s Highflying IPOs From 2013-2014
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Sep
2015
Join Me for the TR San Francisco Launch Party Oct. 20
I’m coming to San Francisco next month, and looking forward to a party. Mark your calendars for 5 pm Oct. 20 for the Timmerman Report’s San Francisco Launch Party. This special event will be held at Invitae at 475 Brannan St. in SF’s SoMa district. It will be free, but requires an advance RSVP. San Francisco Bay Area readers have... Read More
31
Aug
2015
What Happens After the Hype? A Few Survive the ‘Trough of Disillusionment’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Aug
2015
Insider Stock Sales at Biotech’s Big Six: See Who’s Cashing Out the Most
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.